Toxic pneumonitis caused by inhalation of hydrocarbon waterproofing spray in two dogs     

Young BC  Strom AM  Prittie JE  Barton LJ 《Journal of the American Veterinary Medical Association》2007,231(1):74-78

CASE DESCRIPTION: 2 dogs were evaluated because of vomiting and lethargy (a Toy Poodle; dog 1) and acute respiratory distress, vomiting, and anorexia (a Chihuahua; dog 2). Dog 1 had been exposed to a commercial hydrocarbon waterproofing spray 24 hours before the development of clinical signs, and dog 2 was examined 18 hours after exposure to a waterproofing spray containing heptane, a highly flammable liquid hydrocarbon. CLINICAL FINDINGS: In both dogs, major gastrointestinal tract abnormalities were ruled out but respiratory status worsened. Thoracic radiography revealed a diffuse interstitial pulmonary pattern, and hypoxemia was detected. TREATMENT AND OUTCOME: Hospitalization for monitoring and care was required for both dogs. The dogs recovered with supportive care, which included administration of oxygen, fluids, and bronchodilators. Additionally, dog 1 received glucocorticoids via inhalation and supplemental enteral nutrition, whereas dog 2 was treated with an antimicrobial. CLINICAL RELEVANCE: The dogs of this report developed hydrocarbon pneumonitis following exposure to waterproofing sprays. Such sprays contain potentially toxic hydrocarbons. The severity of the adverse effects associated with exposure may have been amplified because the dogs were physically small and were exposed to a relatively large amount of aerosolized spray within small areas. Development of chemical pneumonitis in pet animals is best prevented by application of waterproofing sprays in well-ventilated or outdoor areas from which pets have been excluded. With prolonged hospitalization and considerable monitoring and care, affected dogs can recover from these exposures.  相似文献   

Suspected panosteitis in a camel     

Levine DG  Smith JJ  Richardson DW  Brown V  Beech J  Habecker P  Adam E 《Journal of the American Veterinary Medical Association》2007,231(3):437-441

CASE DESCRIPTION: A 6-month-old male Bactrian camel was examined because of a 3-week history of lameness of the left hind limb. CLINICAL FINDINGS: Lameness was initially detected in the left hind limb but resolved and was detected in the right hind limb during treatment. Lameness increased during periods of rapid growth. Radiography revealed multiple small opacities of the medullary cavity of several long bones throughout treatment. Core bone biopsies of lesions in the tibiae revealed lamellar bone with areas of loose connective tissue, osteoblasts in the medullary cavity, and periosteal new bone formation, all which were consistent with panosteitis. TREATMENT AND OUTCOME: Palliative treatment was attempted with epidural and transdermal administration of analgesics. Flunixin meglumine was administered PO, which coincided with an abrupt increase in serum creatinine concentration. Performance of multiple diagnostic bone biopsies led to remission of clinical signs of pain. CLINICAL RELEVANCE: Panosteitis should be a differential diagnosis for shifting limb lameness in young camels. Bone biopsies can be useful for diagnosis of panosteitis and possible relief of pain associated with the disease. Bactrian camels may be susceptible to the renal toxicity of flunixin meglumine, especially when dehydrated.  相似文献   

Treatment of doxorubicin extravasation with intravenous dexrazoxane in a cat     

Mahoney JA  Bergman PJ  Camps-Palau MA  Hull TL 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2007,21(4):872-873

  相似文献   

Diagnosis and treatment of a selective immunoglobulin M glomerulonephropathy in a quarter horse gelding     

Mcsloy A  Poulsen K  Fisher PJ  Armien A  Chilton JA  Peek S 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2007,21(4):874-877

  相似文献   

Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma     

Sorenmo K  Samluk M  Clifford C  Baez J  Barrett JS  Poppenga R  Overley B  Skorupski K  Oberthaler K  Van Winkle T  Seiler G  Shofer F 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2007,21(6):1347-1354

BACKGROUND: Canine splenic hemangiosarcoma (HSA) is a fatal malignancy, and most affected dogs die within a few months of diagnosis. Most dogs present with signs from tumor rupture, resulting in hemoabdomen and intra-abdominal dissemination. The abdomen is also the main site of disease recurrence. HYPOTHESIS: Intraperitoneal (IP) administration of doxorubicin will delay or prevent intra-abdominal tumor recurrence and prolong survival in dogs with HSA. ANIMALS: Fourteen dogs with splenic HSA. METHODS: A prospective, unmasked, uncontrolled clinical trial. After staging of disease status and splenectomy, pegylated liposomal encapsulated doxorubicin was administered intraperitoneally (1 mg/kg body weight) every 3 weeks for 4 cycles. All dogs were monitored for recurrence of HSA. Samples of plasma and abdominal fluid were collected for measurement of doxorubicin concentration and pharmacokinetic analysis. Nonlinear mixed-effect modeling was used to describe the pharmacokinetics of liposomal doxorubicin administered IP. RESULTS: All 14 dogs died, 12 because of HSA and 2 from other causes. Postmortem examination was performed on 12 dogs. All 12 dogs died because of HSA-related causes and had hepatic metastases and hemoabdomen. The IP-treated dogs had fewer serosal, mesenteric, and omental metastases than historical controls treated with systemic doxorubicin. Results of the postmortem examination and pharmacokinetic analysis confirmed that IP delivery of doxorubicin resulted in an effective drug concentration with a clearance comparable with that after i.v. delivery. CONCLUSIONS AND CLINICAL IMPORTANCE: IP pegylated liposomal encapsulated doxorubicin administration did not prevent intraabdominal recurrence of HSA in dogs.  相似文献   

小菜蛾响应⁶⁰Co-γ辐照的实验室种群生命表     

杨雨航  陈雅余  王梦然  李丹宁  王欣蕾  翁群芳 《植物保护学报》2023,50(2):493-500

为明确⁶⁰Co-γ亚不育剂量辐照对小菜蛾Plutella xylostella种群数量动态变化的影响,构建小菜蛾种群动态变化模型,在实验室条件下通过建立小菜蛾生命表获得种群特征参数、个体生理指标,预测亚不育剂量辐照对小菜蛾种群的影响。结果显示,亚不育剂量辐照组的羽化率显著高于完全不育剂量组,与空白对照组无显著差异,各处理羽化率无性别差异,亚不育剂量辐照组F1代孵化率显著低于空白对照组。亚不育剂量辐照组种群各阶段发育历期、存活率及繁殖力生命指标低于空白对照组。小菜蛾亚不育剂量辐照组世代平均历期(19.90 d)、世代净生殖率(2.35)、周限增长率(1.04 d-1)、内禀增长率(0.04 d-1)均低于空白对照组,而种群加倍时间(16.16 d)高于空白对照组。空白对照组世代平均历期、每日单雌产卵量与产卵时间均长于亚不育剂量辐照组。辐照组与对照组种群生命表参数对比,表明亚不育剂量降低了小菜蛾种群世代数和幼虫期的个体存活率,使F1代雌虫个体数减少。  相似文献   

Fractionated oral dosing and its effect on cyclophosphamide pharmacokinetics in dogs with high-grade multicentric lymphoma     

Sridhar Veluvolu  Jennifer L. Willcox  Katherine A. Skorupski  Sami Al-Nadaf  Robert Rebhun  Luke Wittenburg 《Veterinary and comparative oncology》2023,21(1):20-27

Cyclophosphamide (CP) is an alkylating agent commonly included in multi-drug treatment protocols for canine cancer. As a prodrug, CP requires hepatic metabolism for activation to the intermediate compound 4-hydroxycyclophosphamide (4-OHCP) which then spontaneously forms alkylating phosphoramide mustard. CP is frequently administered in a fractionated manner, with the total dose given over multiple days. CP is reported to cause auto-induction of metabolism in humans, with faster CP clearance and relatively increased 4-OHCP formation following fractionated versus bolus dosing, however canine pharmacokinetic studies of CP dose fractionation are lacking. The study objective was to evaluate the pharmacokinetics of fractionated oral CP dosing at a dose of 200–250 mg/m² over 3 to 4 days in a prospectively identified population of cancer-bearing dogs. Plasma concentrations of CP and 4-OHCP were measured by ultra-high performance liquid chromatography tandem-mass spectrometry in eight dogs following the first and last doses to assess for auto-induction of CP metabolism. No significant difference in the rate of CP elimination between first and last doses were detected (0.73 ± 0.46 vs. 1.22 ± 0.5 h⁻¹; p = .125). Additionally, no significant difference in dose-normalized 4-OHCP exposure was identified between first and last doses (5.9 ± 2.1 vs. 7.9 ± 6.4 h × ng/ml; p = .936). These results suggest that fractionated dosing may not increase exposure to the active metabolite of CP in dogs as it does in humans. As such, standard bolus dosing and fractionated dosing may be equivalent in terms of bio-activation of CP in dogs administered a dose of 200–250 mg/m².  相似文献   

Evaluation of mechlorethamine,vinblastine, procarbazine,and prednisone for the treatment of resistant multicentric canine lymphoma     

Kelley Zimmerman  Koranda A. Walsh  Jonathan T. Ferrari  Nicholas S. Keuler  Matthew J. Atherton  Jennifer A. Lenz 《Veterinary and comparative oncology》2023,21(3):503-508

Multi-agent chemotherapy successfully induces remission in most naïve, high-grade canine lymphoma patients; however, disease recurrence is common. MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) is an effective rescue protocol used to re-induce remission, but is associated with gastrointestinal toxicity and can be a less desirable option for patients that previously failed vincristine-containing protocols. Therefore, alternative members of the vinca alkaloid family, such as vinblastine, could be potentially advantageous as substitutes for vincristine to reduce gastrointestinal toxicity and chemoresistance. The objective of this study was to report the clinical outcomes and toxicity of 36 dogs with relapsed or refractory multicentric lymphoma treated with a modified MOPP protocol whereby vincristine was replaced with vinblastine (MVPP). The overall response rate to MVPP was 25% with a median progression free survival of 15 days and a median overall survival of 45 days. MVPP at the prescribed doses resulted in modest and transient clinical benefit, but was well tolerated with no treatment delays or hospitalizations secondary to side effects. Given the minimal toxicity, dose intensification could be considered to improve clinical responses.  相似文献   

Highly recurrent BRAF p.V595E mutation in canine papillary oral squamous cell carcinoma     

Santiago Peralta  Suzin M. Webb  William P. Katt  Jennifer K. Grenier  Gerald E. Duhamel 《Veterinary and comparative oncology》2023,21(1):138-144

Oral squamous cell carcinoma (OSCC) is the most common oral epithelial malignancy in dogs. It exhibits locally aggressive biological behaviour with the potential to metastasize, and a reported 1-year survival rate of 0% when left untreated. Expression studies suggest that aberrant MAPK signalling plays a key role in canine OSCC tumorigenesis, which is consistent with BRAF and HRAS MAPK-activating mutations reported in some tumours. Several morphological subtypes of canine OSCC have been described, with papillary, conventional, and basaloid as the most common patterns. We hypothesized that mutational differences may underlie these phenotypic variations. In this study, targeted Sanger sequencing and restriction fragment length polymorphism assays demonstrate that up to 85.7% of canine papillary OSCC (n = 14) harbour a BRAF p.V595E mutation. Assessment of neoplastic epithelial cell proliferation using Ki67 immunolabelling (n = 10) confirmed a relatively high proliferation activity, consistent with their known aggressive clinical behaviour. These findings underscore a consistent genetic feature of canine papillary OSCC and provide a basis for the development of novel diagnostic and targeted therapeutic approaches that can improve the quality of veterinary care.  相似文献   

The use of intralipid emulsion therapy to treat status epilepticus in a guinea pig (Cavia porcellus) secondary to severe ivermectin toxicity     

Jennifer J. Ebel DVM  Kristi Gannon DVM  DACVECC  Mara Kraenzlin VMD  DACVECC 《Journal of Veterinary Emergency and Critical Care》2023,33(1):107-111

  相似文献